IndustryCompany release

Mesoblast chair says firm is pivoting to commercial execution as Ryoncil earns about US$115m

Mesoblast Ltd (MESO) · Thu 12 Nov 2026

At the 2026 AGM, Mesoblast's chair described a shift from research-led business to commercial focus, citing roughly US$115 million in fiscal 2026 net sales of Ryoncil.

Mesoblast's chair told the company's 2026 annual general meeting that the business is moving away from a research-driven model and towards commercial execution.

The shift follows the performance of Ryoncil (remestemcel-L-rknd), which is approved for paediatric steroid-refractory acute graft-versus-host disease (GvHD). The product generated roughly US$115 million in net sales in fiscal 2026, according to the chair's remarks.

The chair also gave updates on the pipeline. Enrolment is complete in the Phase 3 trial of rexlemestrocel-L in chronic low back pain, while enrolment has begun in a registrational trial of Ryoncil in adults.

Shareholders were also asked to vote on a director nominee standing for election at the meeting. The source material available does not give further detail on the nominee, trial timelines or sales breakdowns.

What it means for your team

  • Ryoncil's roughly US$115 million in fiscal 2026 net sales offers a early data point on commercial uptake of an approved cell therapy in paediatric GvHD.
  • The registrational adult Ryoncil trial signals a possible label-expansion path; regulatory teams should watch for protocol and filing details when they emerge.
  • Completed enrolment in the Phase 3 low back pain trial for rexlemestrocel-L moves that programme closer to a data readout, though no timing was given.
  • Pharmacovigilance and market-access teams tracking cell therapies may expect a larger commercial footprint to bring more real-world safety and reimbursement activity.

Company's press release (SEC filing): Mesoblast Ltd ↗

Article written by VigiEye from the official source (Mesoblast Ltd). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →